- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.01. | A happier new year? | ||
| 25.01. | Merck ends its COVID-19 vaccine programme after disappointing early trial results | ||
| 25.01. | AstraZeneca reduces initial COVID-19 vaccine deliveries to the EU | ||
| 25.01. | Pfizer/BioNTech reach vaccine supply agreement with COVAX | ||
| 25.01. | BMS gains FDA approval for second Opdivo combo in kidney cancer | ||
| 25.01. | An EU emergency health fund to limit the impact of future crises | ||
| 22.01. | UPDATED: Gilead says remdesivir likely to be effective against new COVID-19 strains | ||
| 22.01. | FDA priority review for Roche's Esbriet in unclassifiable interstitial lung disease | ||
| 22.01. | Lilly's antibody bamlanivimab cuts COVID-19 risk by up to 80% | ||
| 22.01. | Gilead's Jyseleca is given a NICE recommendation for rheumatoid arthritis | ||
| 22.01. | Janet Woodcock named acting commissioner of the FDA | ||
| 22.01. | 3 Monkeys Zeno taps Avril Lee to lead UK and EU healthcare business | ||
| 22.01. | In plain sight | ||
| 21.01. | Lateral flow tests detect 'most infectious' COVID-19 cases, Oxford researchers find | ||
| 21.01. | Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA's cancer alliance | ||
| 21.01. | Pfizer/BioNTech's COVID-19 vaccine found to be effective against UK virus variant | ||
| 21.01. | BMS aims for US approval of Opdivo combo in stomach cancer | ||
| 21.01. | The pandemic preparedness paradox | ||
| 20.01. | Merck's appeal to restore hepatitis C patent verdict against Gilead fails | ||
| 20.01. | Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions | ||
| 20.01. | Trial combining British and Russian COVID-19 vaccines could begin in February | ||
| 20.01. | New Oxford research institute established to tackle antimicrobial resistance | ||
| 20.01. | David Eatwell joins Porterhouse Insights | ||
| 20.01. | Relics from the past | ||
| 19.01. | EU proposes vaccine-sharing mechanism with low-income countries |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
